Avalyn Pharma Shows AP01 Lung Distribution Data, Patient-Centered…

Event summary

Avalyn Pharma presented new data at ERS Congress 2026 showing AP01's predicted aerosol distribution in healthy and fibrotic lungs.
In silico modeling demonstrated robust AP01 delivery to sites of active fibrotic disease, even in severe IPF cases.
Patient survey findings highlighted preferences for clear communication and reduced logistical burden in clinical trial design.
AP01 is currently being evaluated in a global Phase 2b clinical trial (MIST) for progressive pulmonary fibrosis (PPF).
Avalyn also advancing AP02 and AP03 programs for inhaled antifibrotic therapies.

The big picture

Avalyn's presentation at ERS 2026 underscores the growing emphasis on patient-centric clinical trial design in rare respiratory diseases. The company's focus on inhaled therapies for pulmonary fibrosis aligns with broader industry trends toward targeted drug delivery to minimize systemic side effects. With multiple programs in development, Avalyn is positioning itself as a key player in transforming the treatment paradigm for these serious conditions.

What we're watching

Clinical Trial Design: How Avalyn implements patient-centered trial design elements to improve engagement and recruitment.
Regulatory Pathway: The pace at which AP01 advances through Phase 2b trials and potential regulatory milestones.
Competitive Positioning: Whether Avalyn's inhaled antifibrotic approach can differentiate itself in the pulmonary fibrosis market.